Global Partnership Launches Affordable HIV Prevention to End Epidemic
TL;DR Summary
Cheap supplies of the groundbreaking HIV prevention injection lenacapavir will be available in many poorer countries from 2027 at $40 per patient per year, potentially transforming efforts to end the global HIV epidemic, with support from major health organizations and generic drug manufacturers.
- Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic The Guardian
- Philanthropies Strike a Promising Deal to Turn Back H.I.V. The New York Times
- Landmark deal paves way for cheaper HIV protection jab bbc.com
- Gates Foundation Partners With Indian Drugmakers to Speed Rollout of $40 HIV Shot Bloomberg.com
- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 Centers for Disease Control and Prevention | CDC (.gov)
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
94%
759 → 43 words
Want the full story? Read the original article
Read on The Guardian